IPO - Avalo Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-06-05

Corporate Action: Ipo

Type: New

Accession Number: 000162828025029637

Filing Summary: On June 5, 2025, Avalo Therapeutics, Inc. entered into a sales agreement with TD Securities (USA) LLC, allowing the company to offer and sell shares of its common stock up to an aggregate price of $75,000,000. This offering comes as part of a shelf registration statement, providing flexibility for future capital raises. As of the last reported sale on May 29, 2025, the common stock was priced at $3.72 per share. The common stock trades on the Nasdaq under the symbol 'AVTX'. The prospectus outlines that the funds raised will mainly be utilized for ongoing clinical development of the company's lead asset, AVTX-009, along with general corporate purposes. The sales of the common stock may occur through various negotiated transactions, and the Agent is entitled to up to a 3.0% commission on gross sales. Avalo is classified as a smaller reporting company, facilitating reduced disclosure obligations. The document emphasizes the associated risks of investment and limitations on future dividend payments, indicating a strategy focused on growth rather than immediate returns to shareholders.